1st Quarter 2020 Results

1st Quarter 2020 Sales

$20.7B 3.3% | Excluding acquisitions/ divestitures on an operational basis

Worldwide

Diluted Earnings Per Share

$2.17 | Increased 56.1%

Adjusted Diluted Earnings Per Share*

$2.30 | Increased 9.5%

Worldwide Internationally 5.6%

"With Johnson & Johnson's century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic. Johnson & Johnson is built for times like this, and we are leveraging our scientific expertise, operational scale and financial strength in the effort to advance the work on our lead COVID-19 vaccine candidate. We are committed to beginning production at risk imminently and bringing an affordable and accessible vaccine to the public on a not-for-profit basis for emergency pandemic use."

Alex Gorsky
Chairman and
Chief Executive Officer
Johnson & Johnson

Worldwide Consumer Health Sales

Consumer Health worldwide reported sales increased 9.2% or 11.3% operationally. Primary operational contributors:

- $3.6 Billion
  - Tylenol
  - Motrin
  - ZARREZ
  - AVEENO
  - Neutrogena
  - Listerine
  - Aveeno
  - Neutrogena
  - Zyrtec

Worldwide Pharmaceutical Sales

Pharmaceutical worldwide reported sales increased 8.7% or 10.1% operationally. Primary operational contributors:

- $11.1 Billion
  - Stelara
  - DARZALEX
  - imbruvica
  - Simgutza
  - Updrax
  - Opsumt
  - Tremfya
  - Lucentis

Worldwide Medical Devices Sales

Medical Devices worldwide reported sales decreased (8.2)% or (6.9)% operationally. Primary operational contributors:

- $5.9 Billion
  - Surgical Vision
  - Spine
  - Wound Closure
  - Hips
  - Knees
  - Endoscopes
  - Trauma

Note: values may have been rounded


*Non-GAAP financial measures: non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

Non-GAAP measures, excluding the impact of transferred assets.

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events, the important assumption of the risks and uncertainties that could cause actual results to vary materially from those expressed or implied in such statements. For forward-looking statements included in the Johnson & Johnson earnings releases issued on April 14, 2020, as well as any other recent forward-looking statements, Johnson & Johnson Reports on Form 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.